Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis

Pediatric Infectious Disease Journal

Volumn 27, Issue 1, 2008, Pages 27-32

  Kieffer, François ^a   Wallon, Martine ^b   Garcia, Patricia ^c   Thulliez, Philippe ^a   Peyron, François ^b   Franck, Jacqueline ^d  

^a Institut de Puericulture   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

Congenital toxoplasmosis; Retinochoroiditis; Risk factors

Indexed keywords

FANSIDAR; FOLINIC ACID; PYRIMETHAMINE; SPIRAMYCIN; SULFADIAZINE; SULFADOXINE; SULFONAMIDE;

AMNIOCENTESIS; ARTICLE; BRAIN CALCIFICATION; CHORIORETINITIS; CLINICAL EVALUATION; CONGENITAL TOXOPLASMOSIS; EYE EXAMINATION; FEMALE; GENDER; HUMAN; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; MALE; MATERNAL DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEROCONVERSION; TREATMENT DURATION;

EID: 37549072666     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e318134286d     Document Type: Article

References (28)

1. Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics. 2004;113:1567-1572.
2. Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986;1:254-256.
3. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics. 1980;66:767-774.
4. Villena I, Aubert D, Leroux B, et al. Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Reims Toxoplasmosis Group. Scand J Infect Dis. 1998;30: 295-300.
5. Foulon W, Villena I, Stray-Pedersen B, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol. 1999;180: 410-415.
6. Gras L, Gilbert RE, Ades AE, Dunn DT. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol. 2001;30:1309-1313.
7. Gras L, Wallon M, Pollak A, et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr. 2005;94: 1721-1731.
8. The SYROCOT Study Group. Individual patient data meta-analysis of prenatal treatment effect for congenital toxoplasmosis. Lancet. 2007; 369:115-122.
9. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. 1999;353:1829-1833.
10. Binquet C, Wallon M, Quantin C, et al. Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis. Epidemiol Infect. 2003;131:1157-1168.
11. Romand S, Wallon M, Franck J, Thulliez P, Peyron F, Dumon H. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet Gynecol. 2001;97:296-300.
12. Lebech M, Joynson DH, Seitz HM, et al. Classification system and case definitions of Toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. European Research Network on Congenital Toxoplasmosis. Eur J Clin Microbiol Infect Dis. 1996;15:799-805.
13. Gilbert R, Gras L. European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. Br J Obst Gynaecol. 2003;110:112-120.
14. Djurkovic-Djakovic O, Romand S, Nobre R, Couvreur J, Thulliez P. Serologic rebounds after one-year-long treatment for congenital toxoplasmosis. Pediatr Infect Dis J. 2000;19:81-83.
15. Wallon M, Cozon G, Ecochard R, Lewin P, Peyron F. Serological rebound in congenital toxoplasmosis: long-term follow-up of 133 children. Eur J Pediatr. 2001;160:534-540.
16. Gilbert RE, Stanford MR. Is ocular toxoplasmosis caused by prenatal or postnatal infection? Br J Ophthalmol. 2000;84:224-226.
17. Chapman DJ, Ashburn D, Ogston SA, Ho-Yen DO. The relationship between ocular toxoplasmosis and levels of specific toxoplasma antibodies. Epidemiol Infect. 1999;122:299-303.
18. Glasner PD, Silveira C, Kruszon-Moran D, et al. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol. 1992;114:136-144.
19. Walker W, Roberts CW, Ferguson DJ, Jebbari H, Alexander J. Innate immunity to Toxoplasma gondii is influenced by gender and is associated with differences in interleukin-12 and gamma interferon production. Infect Immun. 1997;65:1119-1121.
20. Roberts CW, Cruickshank SM, Alexander J. Sex-determined resistance to Toxoplasma gondii is associated with temporal differences in cytokine production. Infect Immun. 1995;63:2549-2555.
21. Pung OJ, Luster MI. Toxoplasma gondii: decreased resistance to infection in mice due to estrogen. Exp Parasitol. 1986;61:48-56.
22. Daffos F, Forestier F, Capella-Pavlovsky M, et al. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med. 1988;318:271-275.
23. Berrebi A, Kobuch WE, Bessieres MH, et al. Termination of pregnancy for maternal toxoplasmosis. Lancet. 1994;344:36-39.
24. McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the national collaborative Chicago-based, congenital toxoplasmosis study. Clin Infect Dis. 2006;42:1383-1394.
25. Patel DV, Holfels EM, Vogel NP, et al. Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis. Radiology. 1996;199:433-440.
26. Nakagawa TA, Skrinska R. Improved documentation of retinal hemorrhages using a wide-field digital ophthalmic camera in patients who experienced abusive head trauma. Arch Pediatr Adolesc Med. 2001;155: 1149-1152.
27. Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med. 1994;330:1858-1863.
28. Roberts F, Mets MB, Ferguson DJ, et al. Histopathological features of ocular toxoplasmosis in the fetus and infant. Arch Ophthalmol. 2001; 119:51-58.